Guiling Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guiling Yang has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Yuanxiang Jin
Zhejiang University of Technology
12 shared publications Dou Wang
State Key Laboratory for Quality and Safety of Agro-Products, Institute of Agro-Product Safety and Nutrition, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China
10 shared publicationsYao Zhao
Xianghu Laboratory, Hangzhou, China
10 shared publications- Jintao Cheng
Xianghu Laboratory, Hangzhou, China
7 shared publications Yuanxiang Jin
Xianghu Laboratory, Hangzhou, 311231, China
7 shared publicationsBaoxian Li
College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China
6 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Springer Nature in Bioresources and Bioprocessing
- Vol. 13 (1) , 132
Bacillus subtilis extracellular vesicles surface-displaying superoxide dismutase attenuate alcoholic liver injury by activating the Nrf2/HO-1 axis
- 12 September 2026
- Published by Springer Nature in Bioresources and Bioprocessing
- Vol. 13 (1) , 132
Open AccessBacillus subtilis extracellular vesicles surface-displaying superoxide dismutase attenuate alcoholic liver injury by activating the Nrf2/HO-1 axis
- Open Access
- 28 May 2026
- Published by OAE Publishing Inc. in Extracellular Vesicles and Circulating Nucleic Acids
- Vol. 7 (2) , 714-46
Engineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects
Postbiotics, defined as inactivated microorganisms and/or their components conferring a health benefit, represent a paradigm shift from traditional probiotics by offering superior safety, stability, and precise dosing. Bacterial extracellular vesicles (BEVs), natural nanoparticles secreted by bacteria, are key mediators of microbiota-host communication. BEVs have emerged as promising natural postbiotic agents due to their ability to transport bioactive cargo and modulate host physiology. However, the therapeutic application of natural BEVs (nBEVs) is constrained by limitations, including potential safety concerns, lack of target specificity, low yield, and compositional heterogeneity. To overcome these barriers, the concept of engineered BEVs (eBEVs) has been introduced. By employing genetic modification of parent bacteria, surface functionalization, and tailored cargo loading, eBEVs can be precisely designed. This engineering transforms nBEVs into advanced, targeted delivery platforms that significantly expand the scope and efficacy of postbiotics. This review explores the vast potential of eBEVs as next-generation precision postbiotics to treat multiple disorders. Despite the transformative potential, translating eBEVs into clinical practice faces challenges. These include scalable manufacturing processes, comprehensive in vivo safety and pharmacokinetic profiling, and the establishment of regulatory frameworks. Future progress hinges on interdisciplinary efforts to develop smart, stimulus-responsive BEVs, enhance endosomal escape efficiency, and conduct rigorous clinical trials. Ultimately, eBEVs stand at the forefront of a new era in microbiota-based therapeutics, merging the biocompatibility of natural vesicles with the precision of synthetic nanomedicine.
- 28 May 2026
- Published by OAE Publishing Inc. in Extracellular Vesicles and Circulating Nucleic Acids
- Vol. 7 (2) , 714-46
Open AccessEngineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects
Postbiotics, defined as inactivated microorganisms and/or their components conferring a health benefit, represent a paradigm shift from traditional probiotics by offering superior safety, stability, and precise dosing. Bacterial extracellular vesicles (BEVs), natural nanoparticles secreted by bacteria, are key mediators of microbiota-host communication. BEVs have emerged as promising natural postbiotic agents due to their ability to transport bioactive cargo and modulate host physiology. However, the therapeutic application of natural BEVs (nBEVs) is constrained by limitations, including potential safety concerns, lack of target specificity, low yield, and compositional heterogeneity. To overcome these barriers, the concept of engineered BEVs (eBEVs) has been introduced. By employing genetic modification of parent bacteria, surface functionalization, and tailored cargo loading, eBEVs can be precisely designed. This engineering transforms nBEVs into advanced, targeted delivery platforms that significantly expand the scope and efficacy of postbiotics. This review explores the vast potential of eBEVs as next-generation precision postbiotics to treat multiple disorders. Despite the transformative potential, translating eBEVs into clinical practice faces challenges. These include scalable manufacturing processes, comprehensive in vivo safety and pharmacokinetic profiling, and the establishment of regulatory frameworks. Future progress hinges on interdisciplinary efforts to develop smart, stimulus-responsive BEVs, enhance endosomal escape efficiency, and conduct rigorous clinical trials. Ultimately, eBEVs stand at the forefront of a new era in microbiota-based therapeutics, merging the biocompatibility of natural vesicles with the precision of synthetic nanomedicine.
- Top Cited PapersOpen Access
- 1 March 2026
- Published by KEAI Publishing in Synthetic and Systems Biotechnology
- Vol. 11, 370-384
Engineering genetic elements for microbial protein expression systems: Advances, challenges, applications, and prospects
The rising global demand for sustainable protein sources poses critical challenges across food, pharmaceutical, and industrial biotechnology sectors. Microbial expression systems provide scalable and versatile platforms for producing recombinant proteins, including enzymes, therapeutic molecules, and functional food ingredients. These platforms enable efficient biosynthesis of high-value proteins from renewable substrates often via precision fermentation, surpassing conventional methods in yield, cost-efficiency, and environmental sustainability. This review summarizes the genetic regulatory elements that govern gene expression in microbial hosts, with comparative coverage of prokaryotic and eukaryotic systems at transcriptional and translational levels. Key regulatory components, such as promoters, ribosome binding sites (RBS), untranslated regions (UTRs), signal peptides, and terminators, are discussed in the context of host-specific engineering strategies. We highlight advanced engineering approaches, including artificial intelligence (AI) assisted sequence design, CRISPR-Cas-based genome editing, and modular combinatorial optimization of genetic elements. Particular attention is given to the integration of high-throughput screening and predictive modeling tools that accelerate the rational design and optimization of microbial production systems. The review also discusses practical applications in food, pharmaceutical, and industrial enzyme production, emphasizing how genetic element engineering bridges fundamental research and biomanufacturing. Finally, key challenges and future prospects are analyzed to guide the development of next-generation microbial cell factories for sustainable protein production and industrial innovation.
- 1 March 2026
- Published by KEAI Publishing in Synthetic and Systems Biotechnology
- Vol. 11, 370-384
Top Cited PapersOpen AccessEngineering genetic elements for microbial protein expression systems: Advances, challenges, applications, and prospects
The rising global demand for sustainable protein sources poses critical challenges across food, pharmaceutical, and industrial biotechnology sectors. Microbial expression systems provide scalable and versatile platforms for producing recombinant proteins, including enzymes, therapeutic molecules, and functional food ingredients. These platforms enable efficient biosynthesis of high-value proteins from renewable substrates often via precision fermentation, surpassing conventional methods in yield, cost-efficiency, and environmental sustainability. This review summarizes the genetic regulatory elements that govern gene expression in microbial hosts, with comparative coverage of prokaryotic and eukaryotic systems at transcriptional and translational levels. Key regulatory components, such as promoters, ribosome binding sites (RBS), untranslated regions (UTRs), signal peptides, and terminators, are discussed in the context of host-specific engineering strategies. We highlight advanced engineering approaches, including artificial intelligence (AI) assisted sequence design, CRISPR-Cas-based genome editing, and modular combinatorial optimization of genetic elements. Particular attention is given to the integration of high-throughput screening and predictive modeling tools that accelerate the rational design and optimization of microbial production systems. The review also discusses practical applications in food, pharmaceutical, and industrial enzyme production, emphasizing how genetic element engineering bridges fundamental research and biomanufacturing. Finally, key challenges and future prospects are analyzed to guide the development of next-generation microbial cell factories for sustainable protein production and industrial innovation.
- Top Cited Papers
- 1 January 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 339, 150031
Bacillus subtilis-derived extracellular vesicles displaying superoxide dismutase exhibit superior antioxidant ability in ameliorating skin damage
- 1 January 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 339, 150031
Top Cited PapersBacillus subtilis-derived extracellular vesicles displaying superoxide dismutase exhibit superior antioxidant ability in ameliorating skin damage
- 1 November 2025
- Published by Elsevier in Biotechnology Advances
- Vol. 86, 108747
Peroxisome engineering in yeast: Advances, challenges, and prospects
- 1 November 2025
- Published by Elsevier in Biotechnology Advances
- Vol. 86, 108747
Peroxisome engineering in yeast: Advances, challenges, and prospects
- Open Access
In Vitro Gastrointestinal Digestion of Grifola frondosa Polysaccharides and Their Enhancement of GABA Production via Gut Microbiota Modulation
Background: The water-soluble Grifola frondosa polysaccharides (GFPs) are the primary bioactive component of the edible and medicinal fungus Grifola frondosa. However, the digestive behavior of GFPs in the human gastrointestinal (GI) tract and their subsequent interaction with gut microbiota (GM) to exert health effects remain unclear. Methods: In this study, GFPs were extracted based on a traditional hot water decoction. An in vitro simulated GI digestion model and a human fecal microbiota fermentation model were established to systematically investigate the digestive stability of GFPs, GM modulation, and metabolite changes. Results: Results showed that GFPs remained structurally stable during in vitro oral, gastric, and small intestinal digestion, allowing them to reach the colon intact for microbial fermentation. During colonic fermentation, GFPs were efficiently degraded by GM, and significantly increased the relative abundance of beneficial bacteria such as Akkermansia, Bacteroides, Parabacteroides, and Lactobacillus while reducing the abundance of pathogenic Escherichia-Shigella. Meanwhile, GFPs enriched metabolites beneficial for intestinal health, among which γ-aminobutyric acid (GABA) was the most significantly upregulated. Single-strain fermentation confirmed that Lactobacillus (L. plantarum) was the core GABA-producing genus. Conclusions: This study highlights the potential of GFPs as prebiotics for GM modulation, expands the understanding of the health-promoting effects of fungal polysaccharides, and provides a theoretical basis for the development of GFP-based functional foods.
Open AccessIn Vitro Gastrointestinal Digestion of Grifola frondosa Polysaccharides and Their Enhancement of GABA Production via Gut Microbiota Modulation
Background: The water-soluble Grifola frondosa polysaccharides (GFPs) are the primary bioactive component of the edible and medicinal fungus Grifola frondosa. However, the digestive behavior of GFPs in the human gastrointestinal (GI) tract and their subsequent interaction with gut microbiota (GM) to exert health effects remain unclear. Methods: In this study, GFPs were extracted based on a traditional hot water decoction. An in vitro simulated GI digestion model and a human fecal microbiota fermentation model were established to systematically investigate the digestive stability of GFPs, GM modulation, and metabolite changes. Results: Results showed that GFPs remained structurally stable during in vitro oral, gastric, and small intestinal digestion, allowing them to reach the colon intact for microbial fermentation. During colonic fermentation, GFPs were efficiently degraded by GM, and significantly increased the relative abundance of beneficial bacteria such as Akkermansia, Bacteroides, Parabacteroides, and Lactobacillus while reducing the abundance of pathogenic Escherichia-Shigella. Meanwhile, GFPs enriched metabolites beneficial for intestinal health, among which γ-aminobutyric acid (GABA) was the most significantly upregulated. Single-strain fermentation confirmed that Lactobacillus (L. plantarum) was the core GABA-producing genus. Conclusions: This study highlights the potential of GFPs as prebiotics for GM modulation, expands the understanding of the health-promoting effects of fungal polysaccharides, and provides a theoretical basis for the development of GFP-based functional foods.
- Open Access
- 23 July 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 302, 118740
Elucidating the combined toxicity of dimethomorph and difenoconazole: Intergenerational effects on different biological processes in zebrafish
- 23 July 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 302, 118740
Open AccessElucidating the combined toxicity of dimethomorph and difenoconazole: Intergenerational effects on different biological processes in zebrafish
- Open Access
- 1 March 2025
- Published by KEAI Publishing in Synthetic and Systems Biotechnology
- Vol. 10 (1) , 120-126
Development of a green Komagataella phaffii cell factory for sustainable production of plant-derived sesquiterpene (–)-α-bisabolol
(–)-α-Bisabolol is a plant-derived sesquiterpene derived from Eremanthus erythropappus, which can be used as a raw material in cosmetics and has anti-inflammatory function. In this study, we designed six mutation sites of the (–)-α-bisabolol synthase BOS using the plmDCA algorithm. Among these, the F324Y mutation demonstrated exceptional performance, increasing the product yield by 73 %. We constructed a de novo (–)-α-bisabolol biosynthesis pathways through systematic synthetic biology strategies, including the enzyme design of BOS, selection of different linkers in fusion expression, and optimization of the mevalonate pathway, weakening the branching metabolic flow and multi-copy strategies, the yield of (–)-α-bisabolol was significantly increased, which was nearly 35-fold higher than that of the original strain (2.03 mg/L). The engineered strain was capable of producing 69.7 mg/L in shake flasks. To the best of our knowledge, this is the first report on the biosynthesis of (–)-α-bisabolol in Komagataella phaffii, implying this is a robust cell factory for sustainable production of other terpenoids.
- 1 March 2025
- Published by KEAI Publishing in Synthetic and Systems Biotechnology
- Vol. 10 (1) , 120-126
Open AccessDevelopment of a green Komagataella phaffii cell factory for sustainable production of plant-derived sesquiterpene (–)-α-bisabolol
(–)-α-Bisabolol is a plant-derived sesquiterpene derived from Eremanthus erythropappus, which can be used as a raw material in cosmetics and has anti-inflammatory function. In this study, we designed six mutation sites of the (–)-α-bisabolol synthase BOS using the plmDCA algorithm. Among these, the F324Y mutation demonstrated exceptional performance, increasing the product yield by 73 %. We constructed a de novo (–)-α-bisabolol biosynthesis pathways through systematic synthetic biology strategies, including the enzyme design of BOS, selection of different linkers in fusion expression, and optimization of the mevalonate pathway, weakening the branching metabolic flow and multi-copy strategies, the yield of (–)-α-bisabolol was significantly increased, which was nearly 35-fold higher than that of the original strain (2.03 mg/L). The engineered strain was capable of producing 69.7 mg/L in shake flasks. To the best of our knowledge, this is the first report on the biosynthesis of (–)-α-bisabolol in Komagataella phaffii, implying this is a robust cell factory for sustainable production of other terpenoids.
- Open Access
- 21 January 2025
- Published by Springer Nature in Microbial Cell Factories
- Vol. 24 (1) , 1-9
Development of a Komagataella phaffii cell factory for sustainable production of ( +)-valencene
Sesquiterpene ( +)-valencene is a characteristic aroma component from sweet orange fruit, which has a variety of biological activities and is widely used in industrial manufacturing of food, beverage and cosmetics industries. However, at present, the content in plant sources is low, and its yield and quality would be influenced by weather and land, which limit the supply of ( +)-valencene. The rapid development of synthetic biology has accelerated the construction of microbial cell factories and provided an effective alternative method for the production of natural products. In this study, we first introduced the ( +)-valencene synthase into Komagataella phaffii by CRISPR/Cas9 system, and successfully constructed a ( +)-valencene producer with the initial yield of 2.1 mg/L. Subsequently, the ( +)-valencene yield was increased to 8.2 mg/L by fusing farnesyl pyrophosphate synthase with ( +)-valencene synthase using the selected ligation linker. High expression of key genes IDI1, tHMG1, ERG12 and ERG19 enhanced metabolic flux of MVA pathway, and the yield of ( +)-valencene was further increased by 27%. Besides, in-situ deletion of the promoter of ERG9 increased the yield of ( +)-valencene to 48.1 mg/L. Finally, we optimized the copy number of farnesyl pyrophosphate synthase and ( +)-valencene synthase fusion protein, and when the copy number reached three, the yield of ( +)-valencene achieved 173.6 mg/L in shake flask level, which was 82-fold higher than that of the starting strain CaVAL1. The results obtained here suggest that K. phaffii has the potential to efficiently synthesize other terpenoids.
- 21 January 2025
- Published by Springer Nature in Microbial Cell Factories
- Vol. 24 (1) , 1-9
Open AccessDevelopment of a Komagataella phaffii cell factory for sustainable production of ( +)-valencene
Sesquiterpene ( +)-valencene is a characteristic aroma component from sweet orange fruit, which has a variety of biological activities and is widely used in industrial manufacturing of food, beverage and cosmetics industries. However, at present, the content in plant sources is low, and its yield and quality would be influenced by weather and land, which limit the supply of ( +)-valencene. The rapid development of synthetic biology has accelerated the construction of microbial cell factories and provided an effective alternative method for the production of natural products. In this study, we first introduced the ( +)-valencene synthase into Komagataella phaffii by CRISPR/Cas9 system, and successfully constructed a ( +)-valencene producer with the initial yield of 2.1 mg/L. Subsequently, the ( +)-valencene yield was increased to 8.2 mg/L by fusing farnesyl pyrophosphate synthase with ( +)-valencene synthase using the selected ligation linker. High expression of key genes IDI1, tHMG1, ERG12 and ERG19 enhanced metabolic flux of MVA pathway, and the yield of ( +)-valencene was further increased by 27%. Besides, in-situ deletion of the promoter of ERG9 increased the yield of ( +)-valencene to 48.1 mg/L. Finally, we optimized the copy number of farnesyl pyrophosphate synthase and ( +)-valencene synthase fusion protein, and when the copy number reached three, the yield of ( +)-valencene achieved 173.6 mg/L in shake flask level, which was 82-fold higher than that of the starting strain CaVAL1. The results obtained here suggest that K. phaffii has the potential to efficiently synthesize other terpenoids.